We’re excited to share a few key updates from Pulsenmore as we continue to expand our impact in maternal-fetal care. |
FDA authorization, and what it unlocksReceiving FDA De Novo authorization for the Pulsenmore ES imaging and care-from-home system marks an important milestone. It sets the stage for U.S. market expansion, broader clinical adoption, and new partnerships supporting remote prenatal care. This momentum was recently featured on i24 News, highlighting both clinical value and patient perspective, and showing how remote prenatal monitoring is reshaping care experiences. |
Meet us at SMFM 2026, let’s continue the conversation
We’ll soon be heading to SMFM 2026 in Las Vegas.
Visit our booth, attend the scientific abstract presentations, and meet the team to discuss how you can take part in the future of prenatal care. Reach out to set up a meeting at SMFM.
New partnership, ARC Innovation at Sheba Medical Center
We’re proud to announce our collaboration with ARC Innovation at Sheba Medical Center. ARC connects physicians, researchers, startups, and industry to advance healthcare innovation. Being selected as an ARC partner is an honor, and we’re excited to drive clinical impact together.
Webinar recap, the lasting effects of prenatal anxiety
Thank you to everyone who joined our recent webinar. The discussion highlighted meaningful clinical insights and reinforcing the need for collaborative approaches to maternal mental health.
Corporate update, Nasdaq registration
Pulsenmore has filed a public draft registration statement as part of the process to register its shares for trading on the Nasdaq Capital Market. Upon completion, Pulsenmore is expected to become a dual-listed company, trading on Nasdaq (PLSM) alongside its existing TASE listing (PULS)*.
Thank you for being part of Pulsenmore’s journey!
Warm regards,
The Pulsenmore Team


